(Reuters) -Brokerages have raised their year-end targets for the U.S. stocks benchmark S&P 500, spurred by expectations of a “soft landing” for the economy and
Year: 2024
GameStop’s price declines, ‘time decay’ hammer Roaring Kitty’s option position
By Saqib Iqbal Ahmed NEW YORK (Reuters) – The clock is ticking for Keith Gill, the stock influencer known on YouTube as “Roaring Kitty,” to
US small business sentiment up in May, but looming election clouds outlook
(Reuters) – U.S. small-business confidence and hiring plans increased in May to their highest levels of the year, but the looming U.S. presidential election also
Biden to promote Justice Department’s crackdown on illegal gun trafficking
By Andrea Shalal WASHINGTON (Reuters) – U.S. President Joe Biden will announce on Tuesday that the Department of Justice has charged more than 500 defendants
UBS and Credit Suisse’s Swiss units could merge by July 1, executive says
ZURICH (Reuters) – The merger of the Swiss units of UBS and Credit Suisse could be completed as early as July 1, a senior executive
Nvidia sparks chatter over possible Dow inclusion after stock split
(Reuters) – Nvidia’s 10-for-1 stock split aimed at luring retail investors has taken effect, sparking speculation over chances of the artificial intelligence bellwether’s inclusion in
AI is sole focus at Apple’s annual conference
By Aditya Soni and Stephen Nellis (Reuters) – Apple is expected to showcase how it is integrating artificial intelligence across its software suite, including a
Fed’s new economic projections may come with a dose of maybe, maybe not
By Howard Schneider WASHINGTON (Reuters) – Updated economic projections from Federal Reserve officials this week are expected to show fewer interest rate cuts than policymakers
US Senate panel expands probe into BMW use of parts from banned Chinese supplier
WASHINGTON (Reuters) – The chair of the Senate Finance Committee on Monday said he was expanding its probe into German automaker BMW’s use of electronic
Pfizer’s Paxlovid fails as 15-day treatment for long COVID, study finds
By Michael Erman (Reuters) – A 15-day course of Pfizer’s COVID-19 antiviral treatment Paxlovid did not relieve symptoms of long COVID, according a study by